# A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

> **NCT02944955** · PHASE2 · NOT_YET_RECRUITING · sponsor: **BioLite, Inc.** · enrollment: 52 (estimated)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** BLEX 404 Oral Liquid

## Key facts

- **NCT ID:** NCT02944955
- **Lead sponsor:** BioLite, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944955, "A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02944955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*